News Articles

National Institute for Health and Clinical Excellence Maintains Previous Recommendation for... HOOFDDORP, The Netherlands -Wednesday 9 October 2019  

(BUSINESS WIRE) -- Bioventus, a global leader in orthobiologic solutions, has received notice from the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) that it has updated its guidance (MTG12) regarding the use of the EXOGEN Ultrasound Bone Healing...

Bioventus to Co-Develop Next Generation Placental Tissue Product for Knee Osteoarthritis with MTF Biologics -Friday 7 June 2019

(BUSINESS WIRE)-- Bioventus, a global leader in orthobiologic solutions, has entered into a development collaboration agreement with MTF Biologics, the world’s largest tissue bank, to co-develop a next generation placental tissue product for the treatment of painful musculoskeletal...

Bioventus Launches DUROLANE® in Malaysia and Selects Athrotech as Exclusive Distribution Partner -Friday 1 February 2019  

(BUSINESS WIRE)-- Bioventus, a global leader in orthobiologic solutions, is launching DUROLANE, its single-injection joint-fluid osteoarthritis (OA) treatment, in Malaysia and has selected Athrotech as its exclusive distribution partner for the market. OA involves the breakdown, or...

Bioventus Announces First Patients Enrolled in BONES Study for EXOGEN® -Sunday 17 September 2017  

(BUSINESS WIRE) -- Bioventus, a global leader in orthobiologics, today announced the first patients have been enrolled in its BONES (Bioventus Observational Non-interventional EXOGEN Studies) clinical development program. BONES includes three observational, non-interventional, direct-to-patient...

Bioventus to Invest in New Clinical Research for EXOGEN® -Thursday 16 March 2017  

(BUSINESS WIRE)-- Bioventus, a global leader in orthobiologics, today announced it will commission an innovative series of real-world evidence, direct-to-patient studies to further validate the ability of its EXOGEN Ultrasound Bone Healing System to mitigate the risk of a fracture progressing to...

Bioventus Selects MEDSERVICE to Distribute DUROLANE® in Russia -Wednesday 18 January 2017  

(BUSINESS WIRE)-- Bioventus, a leader in orthobiologic solutions, announced it has selected MEDSERVICE to distribute DUROLANE® in Russia. DUROLANE is a single-injection joint-fluid based on a natural, safe and proven technology process called NASHA® which yields stabilized hyaluronic acid...

Bioventus Expands to Mexico with DUROLANE® for Knee Osteoarthritis Patients -Tuesday 15 November 2016  

(BUSINESS WIRE)-- Bioventus, a leader in orthobiologic solutions, has entered the patient care market in Mexico. This announcement reflects the company’s continued growth in international markets and its mission to partner with the health care community to help people resume and enjoy active...

Bioventus Appoints Andrew McCartney Managing Director, International for EMEA -Monday 7 November 2016  

(BUSINESS WIRE)-- Bioventus, a global leader in orthobiologic solutions, today announced the appointment of Andrew McCartney as Managing Director, International for Europe, Middle East and Africa (EMEA). McCartney, who will be responsible for leading the company’s EMEA business and growing...

Bioventus Launches EXOGEN® Ultrasound Bone Healing System in the Kingdom of Saudi Arabia -Monday 19 September 2016  

(BUSINESS WIRE)-- Bioventus, a leader in orthobiologic solutions, today announced the launch of its EXOGEN Ultrasound Bone Healing System in the Kingdom of Saudi Arabia. EXOGEN uses safe, effective low-intensity pulsed ultrasound to help stimulate the body’s natural healing process.1 It...

Bioventus Launches DUROLANE® for Osteoarthritis Patients in Taiwan -Tuesday 5 January 2016

(BUSINESS WIRE)-- Bioventus, a leader in orthobiologic solutions, today announced its entry into the patient care market in Taiwan with the launch of DUROLANE®, a single-injection joint-fluid osteoarthritis (OA) treatment based on a natural, safe and proven technology process called...

Results 1-10 of 10